- Patent enhances Dewpoint’s leadership in discovery of biomolecular aggregation modulators with potential to treat disease
- New technique is the first to measure how compounds enter or partition into condensates to selectively target individual molecules for disease modification
boston, November 14, 2022 /PRNewswire/ — Dew Point Therapeutics announced today that the United States Patent and Trademark Office (USPTO) has issued a patent for “Methods of Characterizing Condensate-Related Properties of Compounds and Uses Thereof” (US Patent No. 11493519), covering new techniques for assigning and identifying compounds that preferentially assign into the condensate of interest.
Biomolecular condensates are molecular assemblies that form through a process called phase separation, similar to the separation of oil and water. Various condensates are known to be important for regulating cellular processes and regulating many different functions of cells, from controlling the rate of biochemical reactions to compartmentalizing proteins and nucleic acids into coordinated transcriptional machinery. Abnormal condensate function has also been linked to human disease, including neurodegeneration and cancer. Condensate science holds great promise for understanding disease origins and discovering breakthrough treatments.
Little is known about the mechanisms that govern the partitioning of compounds into condensates, how compounds can be designed and tested to improve interactions with condensates, and how this information can be used to improve disease treatment.
Dewpoint’s issued patent is the first patented technology for measuring how compounds enter or partition into target condensates. This breakthrough technology will direct compounds to selectively target individual molecules in condensate to modify disease.
“Dewpoint’s technology has broad implications for drug discovery and maximizing drug effectiveness,” said isaac kline, MD, Ph.D., Chief Scientific Officer of Dewpoint. “It opens up a new era of ‘condensate-targeting’ drug discovery by allowing us to direct molecules to condensates of interest. This can affect the activity of a drug by altering local subcellular concentrations, and thus its efficacy. This is a new way of thinking about medicinal chemistry and lead compound optimization, with the potential to improve drug efficacy.”
exist May 2022, Dewpoint was granted a patent for a fundamental platform technology by the USPTO for a technology that identifies molecules capable of altering specific components of biomolecular condensates with high precision. Taken together, the technology claimed by these patents is critical to the discovery of new compounds that can be used to disrupt condensates in specific ways to correct abnormal cell function and maintain rapid therapeutic potential.
About Dewpoint Therapeutics
Dewpoint Therapeutics is the first company to apply the emerging understanding of biomolecular condensates to drug discovery. Dewpoint believes that a large number of conditions have pathways either regulated by condensate or caused by condensate dysfunction.
Dewpoint currently has more than 20 development programs in an ambitious pipeline spanning oncology, neuromuscular, cardiopulmonary and virology indications and is collaborating with leading academic and pharmaceutical partners globally, including Bayer, Merck and Pfizer .dew point scientists at bostondresden and frankfurt Transforming condensate biology into breakthrough treatments for diseases previously thought incurable.
Learn more and follow us on dewpointx.com Twitter and LinkedIn.
Scientists or investors interested in biomolecular condensates can also visit condensates.com for news and updates in the field.
media contact
Janet Bracey
Vice President of Communications and Public Relations
dew point therapy
+1 609-439-3997 | [email protected]
Investor Contact
Scott PetersonPhD
Senior Vice President, Corporate Development and Investor Relations
dew point therapy
[email protected]
Source: Dew Point Therapy
